arXiv.itsnick.co

an independent field guide to 23 million papers from arXiv & OpenAlex — not affiliated with arXiv.org

Computer Science · Artificial Intelligence

Extended Regimen of Combination Recombinant Human Growth Hormone (rhGH), IL-2 and GM-CSF for Immune Reconstruction in Patients with HIV

See on the map

Abstract

Background: Immunotherapy (rhGH, IL-2, GM-CSF) used in conjunction with highly active anti-retroviral therapy (HAART) provides added benefit towards immune reconstruction in patients with HIV. A standard course of IL-2 consists of 6 one month cycles (one cycle: IL-2 7.5 million IU SC BID pulsed for five days of each month). We report our experience with three patients who exhibited sustained responses in their CD4 profiles during treatment with rhGH (Serostim 6mg SC QD), IL-2, GM-CSF (250-300 mcg SC BID either pulsed monthly with IL-2 or given continuously four times per week) and HAART (>2 nRTI?s and>1PI) and thus elected to extend their regimens for a duration of at least 12 cycles (range 12-21 cycles). Complications included mild, self limited flu-like symptoms and minimal localized irritation, none of which prompted discontinuation of treatment. No patients were hospitalized and no oportunistic infections or AIDS related malignancies developed. A clear trend towards increased CD4 percentages and absolute counts is seen which has not waned at 12 to 21 months of therapy (See Table). Our data may indicate that patients require continuous treatment to maintain T-Cell immunity. Significantly, all of the patients maintained HIV viral RNA less than 1000 throughout the study and two of the three patients were transiently negative for DNA (at month six and 12) during the course of treatment. BACKGROUND Highly active antiretroviral therapy combined with recombinant human growth hormone (rhGH), GM-CSF, and IL-2 for a period

More like this